Effects of losartan combined with Bailing capsule on oxidative stress, renal function and microinflammation in patients with chronic kidney disease
10.3760/cma.j.issn.1008-6706.2021.03.002
- VernacularTitle:氯沙坦联合百令胶囊治疗慢性肾脏病对患者氧化应激、肾功能和微炎症状态的影响
- Author:
Bo LIU
- From:
Chinese Journal of Primary Medicine and Pharmacy
2021;28(3):326-329
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effects of losartan combined with Bailing capsule on oxidative stress, renal function and microinflammation in patients with chronic kidney disease. Methods:Ninety-four patients with chronic kidney disease who received treatment in Rong Jun Hospital from September 2018 to September 2019 were included in this study. They were randomly assigned to receive treatment with either oral losartan (control group, n = 47) or oral losartan combined with Bailing capsule (treatment group, n = 47) for 24 weeks. Preoperative and postoperative oxidative stress, renal function and microinflammatory factor level as well as clinical efficacy were compared between the control and treatment groups. Results:Total effective rate in the treatment group was significantly higher than that in the control group [91.49% (43/47) vs. 68.09% (32/47), χ 2 = 7.982, P < 0.05]. After treatment, superoxide dismutase and glutathione peroxidase levels in the treatment group were significantly higher than those in the control group [superoxide dismutase: (138.16 ± 5.67) U/L vs. (119.74 ± 3.64) U/L, glutathione peroxidase: (48.20 ± 3.78) U/L vs. (41.36 ± 3.29) U/L, t =18.742, 9.358, both P < 0.05]. After treatment, malondialdehyde level in the observation group was significantly lower than that in the control group [(2.78 ± 0.32) mmol/L vs. (3.21 ± 0.38) mmol/L, t = 5.934, P < 0.05]. After treatment, serum urea nitrogen [(4.32 ± 0.45) mmol/L] and creatinine [(54.45 ± 8.98) mmol/L] in the treatment group were significantly lower than those in the control group [(6.53 ± 0.62) mmol/L and (78.31 ± 10.16) mmol/L, t = 19.777, 12.063, both P < 0.05]. After treatment, serum levels of tumor necrosis factor-α [(58.36 ± 6.64) μg/L], hypersensitive C-reactive protein [(3.94 ± 1.25) mg/L] and interleukin-18 [(176.58 ± 17.49) ng/L] in the treatment group were significantly lower than those in the control group [(71.32 ± 6.07) μg/L, (6.87 ± 1.49) mg/L and (229.31 ± 20.09) ng/L, t = 9.876, 10.328, 13.572, all P < 0.05]. Conclusion:Losartan combined with Bailing capsule can improve oxidative stress, renal function and microinflammation in patients with chronic kidney disease and can achieve good clinical efficacy.
